Critical Outcome Advances to Fourth Cohort in Phase 1 Study of COTI-2 in Gynecologic Cancers
LONDON, ON and BOSTON, MA--(Marketwired - January 10, 2017) - Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE: COT) (OTCQB: COTQF), a clinical stage biotechnology company advancing a pipeline of targeted …